Reitman ZJ et al. |
Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. |
2014 |
J. Biol. Chem. |
pmid:24986863
|
Santagata S et al. |
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. |
2014 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:24982150
|
Kato Kaneko M et al. |
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. |
2014 |
Cancer Sci. |
pmid:24898068
|
Fathi AT et al. |
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. |
2014 |
Oncologist |
pmid:24760710
|
Elhammali A et al. |
A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. |
2014 |
Cancer Discov |
pmid:24740997
|
Tarhonskaya H et al. |
Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. |
2014 |
Nat Commun |
pmid:24594748
|
Akbay EA et al. |
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. |
2014 |
Genes Dev. |
pmid:24589777
|
Navis AC et al. |
Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG. |
2013 |
Acta Neuropathol Commun |
pmid:24252742
|
Wang JH et al. |
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. |
2013 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:24082129
|
Lu C et al. |
Induction of sarcomas by mutant IDH2. |
2013 |
Genes Dev. |
pmid:24065766
|
Chaumeil MM et al. |
Non-invasive in vivo assessment of IDH1 mutational status in glioma. |
2013 |
Nat Commun |
pmid:24019001
|
McKenney AS and Levine RL |
Isocitrate dehydrogenase mutations in leukemia. |
2013 |
J. Clin. Invest. |
pmid:23999441
|
Andronesi OC et al. |
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. |
2013 |
J. Clin. Invest. |
pmid:23999439
|
Guilhamon P et al. |
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. |
2013 |
Nat Commun |
pmid:23863747
|
Cairns RA and Mak TW |
Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. |
2013 |
Cancer Discov |
pmid:23796461
|
DiNardo CD et al. |
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. |
2013 |
Blood |
pmid:23641016
|
Losman JA and Kaelin WG |
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. |
2013 |
Genes Dev. |
pmid:23630074
|
Choi C et al. |
A comparative study of short- and long-TE ¹H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. |
2013 |
NMR Biomed |
pmid:23592268
|
Nota B et al. |
Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria. |
2013 |
Am. J. Hum. Genet. |
pmid:23561848
|
Wang F et al. |
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. |
2013 |
Science |
pmid:23558173
|